Recent Updates
Recently added Catalysts
EBS

Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021

Thursday, July 15, 2021 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: GAITHERSBURG, Md., July 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 29, 2021 at 5:00 pm eastern time to discuss the financial results for the second quarter of 2021, recent business developments, revenue guidan
Price reaction · baseline $58.59 (2021-07-14 close) · hit after-hours · clean, no other EBS news in the window
day 0 close · peak
+3.1%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+70%
120-day peak, hindsight
Typical move
8%
average across 2 past catalysts
Lead asset
FLU-IGIV
Phase 2 · Influenza A H3N2

Full Press Release Details

GAITHERSBURG, Md., July 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 29, 2021 at 5:00 pm eastern time to discuss the financial results for the second quarter of 2021, recent business developments, revenue guidance for the third quarter of 2021, and financial outlook for full year 2021.
This conference call can be accessed live by telephone or by webcast:
A replay of the call can be accessed from the Emergent website.
About Emergent BioSolutions
Vice President, Investor Relations
Director, Media Relations
ShareAdd on Google
Tags: EBS Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jul 15, 2021

Biotech snapshot

Cash runway
$141M liquidity · $0M/mo burn
Low dilution risk
Lead asset
FLU-IGIVPhase 2
Influenza A H3N2 →

Catalyst track record

+70%
best trade around EBS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for EBS.

See every catalyst's timing & PoA →